Therachon
Webb9 maj 2024 · May 9, 2024 - Updated on June 24, 2024. 2 minutes. Pharma giant Pfizer is acquiring the Swiss biotech Therachon, which is developing a protein drug to boost bone growth in the genetic condition achondroplasia. Pfizer will pay €303M ($340M) upfront, and up to €420M ($470M) dependent on Therachon reaching milestones in the development … Webb8 maj 2024 · Therachon is developing it as a weekly subcutaneous injection for children and adolescents with the disorder. The drug has finished Phase I trials. The European …
Therachon
Did you know?
Webb25 mars 2024 · BASEL, Switzerland, March 25, 2024 /PRNewswire/ -- Therachon AG ("Therachon"), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of innovative ... Webb8 maj 2024 · Therachon is a clinical-stage global biotechnology company focused on the discovery and development of innovative treatment for severe, rare conditions with …
Webb29 aug. 2024 · About Therachon. Therachon is a global biotechnology company focused on developing medicines for rare, genetic diseases that currently have no available treatments. The company’s lead pipeline candidate, TA-46, is a novel protein therapy in development for achondroplasia, the most common form of short-limbed dwarfism. WebbTherachon is a global biotechnology company, focused on developing treatments for rare, genetic diseases that currently have no available treatments. We are committed to the …
Webb8 maj 2024 · Under the terms of the agreement, Pfizer will acquire Therachon for $340 million upfront with an additional $470 million in additional payments contingent on the achievement of key milestones in the development and commercialization of TA-46 for the treatment of achondroplasia, a genetic condition and the most common form of short … Webb2 juli 2024 · Pfizer has announced it has completed its acquisition of US-based Therachon, a clinical stage biotechnology company focusing on rare diseases; the acquisition was first initiated in early May 2024.. According to the terms of the transaction, the Swiss pharma giant has bought Therachon for $340m with a potential $470m additional payments …
Webb25 mars 2024 · Therachon is committed to making a difference in the lives of patients living with serious rare disorders. For more information, please visit …
Webb9 okt. 2024 · BASEL, Switzerland, Oct. 9, 2024 /PRNewswire/ -- Therachon AG ("Therachon"), a clinical-stage biotechnology company focused on treating root causes of rare conditions, today announced the ... bluetooth search ps4WebbDevelopment group, serving as its Global Head for Integration Management and Global Head of Alliance Management. His work included the integration of Wyeth, Hospira, Anacor, Medivation, Therachon, Array and most recently Amplyx. He also directly led the separation of. 09 Apr 2024 21:53:51 bluetooth seat occupancy sensorWebb29 nov. 2024 · Apraglutide, with once-weekly administration, is a potential best-in-class therapeutic for the treatment of short bowel syndrome. BASEL, Switzerland, Nov. 29, 2024 /PRNewswire/ -- Therachon AG ... bluetooth seat alteaWebb30 jan. 2024 · BASEL, Switzerland, Jan. 30, 2024 /PRNewswire/ -- Therachon AG ("Therachon"), a clinical-stage biotechnology company focused on the discovery, development and commercialization of innovative ... bluetooth security camera for mobileWebbTherachon is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of innovative treatments for severe, rare conditions … bluetooth seat ibiza 2011http://therachon.com/research/ bluetooth second monitor for laptopWebbVP Biology at Therachon. Location: Basel, Canton of Basel-Stadt, Switzerland. Dr. Jeffrey Stavenhagen brings 20 years of scientific leadership experience in both the US and … cleethorpes comic con 2023